Doxorubicin and other anthracyclines in cancers : Activity, chemoresistance and its overcoming
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Molecular aspects of medicine - 93(2023) vom: 05. Okt., Seite 101205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mattioli, Roberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80168379AG |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 15.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mam.2023.101205 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360158080 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360158080 | ||
| 003 | DE-627 | ||
| 005 | 20231226082420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mam.2023.101205 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360158080 | ||
| 035 | |a (NLM)37515939 | ||
| 035 | |a (PII)S0098-2997(23)00045-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mattioli, Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Doxorubicin and other anthracyclines in cancers |b Activity, chemoresistance and its overcoming |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 15.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anthracyclines | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Chemotherapeutic drugs | |
| 650 | 4 | |a Mechanisms of action | |
| 650 | 4 | |a Resistance | |
| 650 | 4 | |a Toxicity | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 700 | 1 | |a Ilari, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Colotti, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Mosca, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Fazi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Colotti, Gianni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular aspects of medicine |d 1992 |g 93(2023) vom: 05. Okt., Seite 101205 |w (DE-627)NLM012681059 |x 1872-9452 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2023 |g day:05 |g month:10 |g pages:101205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mam.2023.101205 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2023 |b 05 |c 10 |h 101205 | ||